Quent Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Quent Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-83	Closed	-$180	–	1596
2025 Q3	$180	Buy	+83	New	+$196	﹤0.01%	1392
2025 Q2	–	Sell	-83	Closed	-$276	–	759
2025 Q1	$276	Hold	83	–	–	﹤0.01%	1275
2024 Q4	$614	Hold	83	–	–	﹤0.01%	1265
2024 Q3	$779	Hold	83	–	–	﹤0.01%	1285
2024 Q2	$666	Hold	83	–	–	﹤0.01%	1285
2024 Q1	$1.23K	Hold	83	–	–	﹤0.01%	1279
2023 Q4	$675	Sell	83 -269	-76%	-$1.41K	﹤0.01%	1278
2023 Q3	$1.6K	Hold	352	–	–	﹤0.01%	1204
2023 Q2	$2.48K	Hold	352	–	–	﹤0.01%	1160
2023 Q1	$2.15K	Hold	352	–	–	﹤0.01%	1155
2022 Q4	$2.25K	Sell	352 -59	-14%	-$461	﹤0.01%	1129
2022 Q3	$4K	Hold	411	–	–	﹤0.01%	1008
2022 Q2	$5K	Buy	411 +97	+31%	+$1.27K	﹤0.01%	945
2022 Q1	$5K	Buy	314 +45	+17%	+$696	﹤0.01%	1047
2021 Q4	$5K	Buy	+269	New	+$5.92K	﹤0.01%	917

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quent Capital's IOVA Position: Q4 2025 in Review

Quent Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 83 shares — an estimated $180 sold.

Quent Capital first reported a position in IOVA in Q4 2021 and held it in 15 quarters. The position peaked at $5K in Q2 2022. 263 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

Quent Capital reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
Quent Capital sold 83 Iovance Biotherapeutics shares in Q4 2025, an estimated $180.
Quent Capital first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 15 quarters.
Quent Capital's Iovance Biotherapeutics position peaked at $5K in Q2 2022.
263 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Quent Capital's 13F filing for Q4 2025, filed 29 Jan 2026.